TOPIC
 / company

Shanghai Fosun Pharmaceutical

Phosun Pharma will pay a premium of 36.7 per cent over Monday’s closing price of HK$18 for Henlius. Photo: Reuters

Shanghai biotech firm’s shares soar after Fosun’s US$690 million buyout offer

Henlius joins a wave of companies that have left Hong Kong’s stock market this year, either through privatisation or voluntary delisting having found themselves undervalued.

videocam

Chinese drugs giant, Shenzhen team up to invest in city’s biomedical start-ups

videocam

Fosun Pharma to deliver China-made surgical robots in key medical milestone

videocam

Shanghai Fosun sees mainland demand for Omicron-focused BioNTech shot in Hong Kong

Long queues of mainland Chinese nationals looking to receive the mRNA vaccine have been seen outside Hong Kong clinics following a re-opening of the border.

7
Mainlanders are rushing to Hong Kong for mRNA vaccine. Photo: Reuters

Fosun mulls sale of Indian drug maker Gland valued at US$3.6 billion

A sale of Hyderabad-based Gland, which specialises in injectable drugs such as antibiotics, oncology and cardiology treatments, will help Fosun raise cash and shore up its balance sheet.

Fosun sells assets amid credit downgrades, liquidity pressure

Fosun International has sold some of its peripheral assets to raise almost US$100 million in cash in recent weeks, as credit rating cuts heighten concerns about the conglomerate’s financial strength.

Advertisement
Advertisement

Home-grown vaccine back on the agenda, China energises ‘scientific’ strategy

Remarks by Vice-Premier Liu He suggest vaccine development remains on the agenda for China, with clinical trials of a home-grown Omicron jab having started in Zhejiang.

videocam
27
clinical trials of a home-grown Omicron jab having started in Zhejiang province earlier this month. Photo: Xinhua

Fosun sees profit rise, set to make generic Pfizer, Merck Covid-19 pills

Shanghai Fosun Pharmaceutical Group is looking into which of its existing plants can be used to manufacture generic versions of Pfizer’s nirmatrelvir, which is sold under the Paxlovid brand name, and Merck’s molnupiravir.

videocam

Five Chinese companies approved to make cheaper version of Pfizer’s Covid-19 oral drug

The five Chinese drug makers were among 35 firms to sign non-exclusive sublicensing agreements with the United Nations-backed MPP.

5

Fosun Pharma, CanSino favoured as vaccinations, infections boost prospects

Chinese vaccine producers stand to benefit from a move to speed up jabs for the nation’s 1.4 billion population, as well a sudden surge in infections across Asia, adding to a market-beating rally this year, analysts said.

videocam
People register information as they prepare to receive the Anhui Zhifei Longcom Covid-19 coronavirus vaccine in Fuyang in eastern Anhui province on May 13. Photo: AFP

Fosun unit Yuyuan sets up US$6.4 billion firm to invest in airlines

Yuyuan’s shares rose by the daily limit of 10 per cent to 13.08 yuan on Thursday amid speculation that its aviation investment company would target Hainan Airlines.

Shops operated by Yuyuan in downtown Shanghai. The new entity will be called Yuyuan Aviation Industry Limited Partnership, according to its filing on Thursday. Photo: Getty Images

Fosun unit, BioNTech to form joint venture to make Covid-19 vaccine

The Fosun unit will contribute up to US$100 million of assets including cash and a manufacturing facility, while BioNTech will chip in the licence and know-how.

videocam
56

China seeks to become global vaccine player in wake of Covid-19

The country’s pharmaceutical industry is expanding its production capacity as it gears up to produce 5 billion doses by the end of next year.

videocam
56

BioNTech vaccine agent, Fosun Pharma, eyes M&As in global expansion

Fosun Pharma seeks to expand its global sales by tapping merger and acquisition opportunities and launching innovative drugs in more overseas markets, CEO says in an interview.

videocam
Fosun Pharma is a key unit within mainland conglomerate Fosun International’s health division: Photo: Handout

Exclusive | New BioNTech vaccine batch ready to ship to Hong Kong and Macau, Fosun says

Hong Kong’s health officials last Wednesday abruptly stopped the city’s BioNTech vaccination roll-out on the advice of the vaccine’s supplier, after the scheme’s frontline staff identified 50 defects in the first batch numbered “210102”.

59
People queue for receive the BioNTech jab at the Hiu Kwong Street Sports Centre in Kwun Tong on 16MAR21. Photo: May Tse

Sinopharm profit rises, ready to meet China’s 500 million Covid-19 jabs goal

Sinopharm Holding was ready to deliver the Covid-19 vaccines needed to meet Beijing’s target of more than 500 million vaccinations by June this year, its president said.

videocam

Fosun rushes to ready BioNTech’s Covid-19 vaccine for January use

Shanghai Fosun Pharmaceutical is said to be rushing cold-storage facilities to prepare for possible deployment of BioNTech’s Covid-19 vaccine in China from next month.

videocam
Advertisement
Advertisement

China set for 100 million doses of BioNTech vaccine amid overseas roll-out

China is poised to have a mix of foreign and domestic vaccine stocks for its battle against the pandemic.

videocam
32
A nurse prepares to administer the Pfizer-BioNTech COVID-19 vaccine at Guy's Hospital in London, Britain, on December 8, 2020. Photo: Reuters

Hong Kong stocks drop after Alibaba, China Literature fined for antitrust breaches

The Hang Seng Index slipped 0.4 per cent to 26,389.52 on Monday, after a decline of 1.2 per cent last week. The Shanghai Composite Index, however, rose 0.7 per cent, after its biggest weekly decline last week in more than two months.

Kerry Logistics gears up to deliver Covid-19 vaccines to Hong Kong

Major logistics companies across the world are gearing up to transport the vaccines, which are more fragile than regular shots. The historic urgency and volumes involved pose an unprecedented challenge for these firms.

videocam

Fosun Pharma stock surges after German partner BioNTech’s clinical success

The shares of Shanghai Fosun Pharmaceutical (Group) surged by as much as 20.8 per cent on Tuesday after the success of German partner BioNTech’s Covid-19 vaccine during clinical trials.

videocam
Fosun Phama is working on launching ‘BNT162b2 in mainland China as soon as possible’, says Guo Guangchang, the billionaire chairman of majority shareholder Fosun International. Photo: AFP

Vaccines may curb Covid-19 pandemic by April, Fosun’s German partner says

The world could start to see the effect of vaccinations on the coronavirus pandemic by the second quarter if medicines are approved early next year, says CEO of BioNTech.

videocam
Collective efforts from vaccine developers, scientists and the media will be needed to inform vaccine sceptics to support higher take-up rates, said Ugur Sahin. Photo: Shutterstock

As countries blame each other for pandemic, firms act together on vaccine

Chinese doctor working with German company says global collaboration as much as science will lead to Covid-19 vaccine.

videocam

Covid-19 pandemic is driving Chinese biotech M&A and IPO deals this year

China’s biotechnology M&A transactions have almost doubled this year, while public stock offerings surged as investors scour for opportunities amid a global rush to develop a cure for Covid-19 disease.

Hong Kong-listed biotech firm Henlius edges closer to Star Market listing

Hong Kong-listed Shanghai Henlius Biotech, which developed China’s first monoclonal antibodies biosimilar product last year for cancer treatment, is edging closer to a listing on Shanghai’s Nasdaq-style Star Market.

Scott Liu Shigao, Shanghai Henlius Biotech’s chief executive and co-founder. Photo: Handout

Fosun Pharma to supply Covid-19 vaccine to Hong Kong, Macau once approved

Fosun earlier obtained the licence from Mainz-based BioNTech to exclusively develop and commercialise its mRNA Covid-19 vaccine products in China.

videocam
Fosun has agreed to pay BioNTech a licensing fee of up to US$85 million, besides sales royalties of 35 per cent of future annual gross profit. Photo: Reuters

Fosun Pharma, BioNTech launch coronavirus vaccine trial in China

144 participants in mainland China will receive two shots of the BNT162b1 coronavirus vaccine candidate spaced by 21 days.

videocam

Fosun Pharma soars after Beijing accepts application for vaccine trial

Fosun Pharmaceutical CEO Wu Yifang says the company hopes to begin clinical trial on the vaccine soon and is in close contact with China’s medical watchdog.

videocam
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Shanghai Fosun Pharmaceutical
Shanghai Fosun Pharmaceutical (Group) Co Ltd is a unit of one of China’s largest conglomerates Fosun International.
Chairman / President
Wu Yifang
CEO / Managing Director
Wen Deyong
CFO / Finance Director
Gong Ping
Industry
Pharmaceuticals
Website
fosunpharma.com
Headquarters address
Building A, No. 1289 Yishan Road, Shanghai, China
Stock Code
SEHK:2196, SSE:600196
Year founded
1994
last updated:
30 September, 2024
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement